Which types of cancer are commonly treated with monoclonal antibodies?

Which types of cancer are commonly treated with monoclonal antibodies?

• A. Skin cancers and melanoma
• B. Hematologic malignancies and solid tumors
• C. Carcinomas of the liver only
• D. Bone cancers and sarcomas

Answer: (B)

Monoclonal antibodies are a class of targeted therapies designed to interact with specific antigens on cancer cells. They are widely used in the treatment of various types of cancers, particularly hematologic malignancies such as lymphomas and leukemias, as well as a broader range of solid tumors including breast, lung, and colorectal cancers. By binding to specific proteins on cancer cells, monoclonal antibodies can inhibit tumor growth, promote apoptosis, or mark cells for destruction by the immune system. The versatility of monoclonal antibodies allows them to be effective against multiple tumor types, which is why this choice encompasses both hematologic malignancies and solid tumors. Treatments like rituximab for non-Hodgkin's lymphoma (a hematologic malignancy) and trastuzumab for HER2-positive breast cancer (a solid tumor) highlight their importance in modern oncology. In contrast, the other answer choices are more limited in scope. Skin cancers and melanoma, while they may sometimes be treated with certain monoclonal antibodies, do not encompass the full range of conditions where these therapies are effective. Carcinomas of the liver are typically managed through other treatment modalities, and bone cancers and sarcomas are more challenging to treat with monoclonal antibodies

Monoclonal antibodies are a class of targeted therapies designed to interact with specific antigens on cancer cells. They are widely used in the treatment of various types of cancers, particularly hematologic malignancies such as lymphomas and leukemias, as well as a broader range of solid tumors including breast, lung, and colorectal cancers. By binding to specific proteins on cancer cells, monoclonal antibodies can inhibit tumor growth, promote apoptosis, or mark cells for destruction by the immune system.

The versatility of monoclonal antibodies allows them to be effective against multiple tumor types, which is why this choice encompasses both hematologic malignancies and solid tumors. Treatments like rituximab for non-Hodgkin's lymphoma (a hematologic malignancy) and trastuzumab for HER2-positive breast cancer (a solid tumor) highlight their importance in modern oncology.

In contrast, the other answer choices are more limited in scope. Skin cancers and melanoma, while they may sometimes be treated with certain monoclonal antibodies, do not encompass the full range of conditions where these therapies are effective. Carcinomas of the liver are typically managed through other treatment modalities, and bone cancers and sarcomas are more challenging to treat with monoclonal antibodies